Market closedNon-fractional
Annexon/ANNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Annexon
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Ticker
ANNX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Brisbane, United States
Employees
70
Website
www.annexonbio.com
Annexon Metrics
BasicAdvanced
$651M
Market cap
-
P/E ratio
-$1.37
EPS
1.29
Beta
-
Dividend rate
Price and volume
Market cap
$651M
Beta
1.29
Financial strength
Current ratio
20.615
Quick ratio
20.174
Long term debt to equity
10.873
Total debt to equity
11.732
Management effectiveness
Return on assets (TTM)
-28.60%
Return on equity (TTM)
-50.60%
Valuation
Price to book
2.14
Price to tangible book (TTM)
2.14
Price to free cash flow (TTM)
-4.655
Growth
Earnings per share change (TTM)
-39.94%
3-year earnings per share growth (CAGR)
-24.35%
What the Analysts think about Annexon
Analyst Ratings
Majority rating from 8 analysts.
Annexon Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
-9.71%
Profit margin
0.00%
NaN%
Annexon Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.43
-$0.36
-$0.21
-
Expected
-$0.54
-$0.50
-$0.44
-$0.34
-$0.23
Surprise
-13.56%
-14.47%
-17.34%
-38.47%
-
Annexon News
AllArticlesVideos
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
GlobeNewsWire·2 weeks ago
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Annexon stock?
Annexon (ANNX) has a market cap of $651M as of July 27, 2024.
What is the P/E ratio for Annexon stock?
The price to earnings (P/E) ratio for Annexon (ANNX) stock is 0 as of July 27, 2024.
Does Annexon stock pay dividends?
No, Annexon (ANNX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Annexon dividend payment date?
Annexon (ANNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Annexon?
Annexon (ANNX) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Annexon stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.